Recombinant feline interferon omega

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.